Pulmonary Erdheim-Chester disease successfully treated with vemurafenib

Pulmonary manifestations of Erdheim–Chester disease: clinical characteristics, outcomes and comparison with Langerhans cell histiocytosis

(2021) Ji‐nuo Wang et al.   BRITISH JOURNAL OF HAEMATOLOGY

Thoracic involvement in Erdheim-Chester disease: computed tomography imaging findings and their association with the BRAFV600E mutation

(2018) S. Mojdeh Mirmomen et al.   EUROPEAN RADIOLOGY

Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis

(2018) Eli L. Diamond et al.   JAMA Oncology

Reproducible and Sustained Efficacy of Targeted Therapy With Vemurafenib in Patients With BRAFV600E-Mutated Erdheim-Chester Disease

(2015) Julien Haroche et al.   JOURNAL OF CLINICAL ONCOLOGY

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

(2015) David M. Hyman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

(2015) E. L. Diamond et al.   Cancer Discovery